OrthoPediatrics Corp. (NASDAQ:KIDS) shares gapped up before the market opened on Thursday . The stock had previously closed at $48.41, but opened at $50.00. OrthoPediatrics shares last traded at $49.52, with a volume of 333 shares traded.

A number of equities analysts have issued reports on the company. Zacks Investment Research cut OrthoPediatrics from a “hold” rating to a “sell” rating in a report on Friday, March 12th. Piper Sandler lifted their price objective on OrthoPediatrics from $55.00 to $62.00 in a report on Tuesday. One analyst has rated the stock with a sell rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $54.50.

The business has a fifty day simple moving average of $50.21 and a 200-day simple moving average of $46.70. The firm has a market cap of $976.81 million, a price-to-earnings ratio of -33.62 and a beta of 0.67.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Thursday, March 11th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.46). OrthoPediatrics had a negative net margin of 34.26% and a negative return on equity of 11.57%. As a group, analysts predict that OrthoPediatrics Corp. will post -1.26 EPS for the current year.

In other OrthoPediatrics news, EVP Gregory A. Odle sold 8,193 shares of OrthoPediatrics stock in a transaction dated Monday, March 1st. The stock was sold at an average price of $55.88, for a total transaction of $457,824.84. Following the completion of the sale, the executive vice president now owns 64,288 shares of the company’s stock, valued at $3,592,413.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bernie B. Berry III sold 699 shares of OrthoPediatrics stock in a transaction dated Thursday, February 25th. The stock was sold at an average price of $57.00, for a total value of $39,843.00. Following the sale, the director now directly owns 32,481 shares of the company’s stock, valued at approximately $1,851,417. The disclosure for this sale can be found here. Insiders sold 47,686 shares of company stock worth $2,589,408 in the last 90 days. Corporate insiders own 33.60% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KIDS. BlackRock Inc. lifted its stake in shares of OrthoPediatrics by 4.7% in the 3rd quarter. BlackRock Inc. now owns 889,358 shares of the company’s stock valued at $40,840,000 after acquiring an additional 40,156 shares during the last quarter. State Street Corp increased its holdings in OrthoPediatrics by 17.7% during the 3rd quarter. State Street Corp now owns 364,061 shares of the company’s stock valued at $16,718,000 after purchasing an additional 54,617 shares during the period. JPMorgan Chase & Co. increased its holdings in OrthoPediatrics by 21.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,942 shares of the company’s stock valued at $230,000 after purchasing an additional 866 shares during the period. Great West Life Assurance Co. Can increased its holdings in OrthoPediatrics by 473.2% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,179 shares of the company’s stock valued at $685,000 after purchasing an additional 5,101 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of OrthoPediatrics by 128.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 106,831 shares of the company’s stock worth $4,906,000 after acquiring an additional 60,082 shares during the period. 71.74% of the stock is owned by institutional investors.

About OrthoPediatrics (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Featured Story: How to execute a trade ex-dividend strategy?

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.